Reuters logo
BRIEF-Alkermes says U.S. District Court issued unambiguous opinion in favor of co, U.S. FDA - SEC filing
July 29, 2016 / 4:55 PM / a year ago

BRIEF-Alkermes says U.S. District Court issued unambiguous opinion in favor of co, U.S. FDA - SEC filing

July 29 (Reuters) - Alkermes Plc:

* On July 28 U.S. District Court for District of Columbia issued unambiguous opinion in favor of co and U.S. FDA - SEC filing

* U.S. District Court unambiguous opinion affirming in all respects FDA’s decision to approve Aristada for treatment of schizophrenia

* U.S. District Court unambiguous opinion also "denying action filed by Otsuka for declaratory and injunctive relief" Source text (bit.ly/2aPWyTH) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below